Relation of P-glycoprotein expression with spontaneous in vitro apoptosis in B-cell chronic lymphocytic leukemia

Neoplasma

Volumn 51, Issue 3, 2004, Pages 181-187

  Jamroziak, K ^a   Smolewski, P ^a   Cebula, B ^a   Szmigielska Kaplon, A ^a   Darzynkiewicz, Z ^b   Robak, T ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Apoptosis; B cell chronic lymphocytic leukemia; P glycoprotein

Indexed keywords

ABC TRANSPORTER; CASPASE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; LIPOCORTIN 5; RHODAMINE 123; VERAPAMIL;

ADULT; AGED; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CANCER RESISTANCE; CELL PROTECTION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENDER; HUMAN; HUMAN CELL; IN VITRO STUDY; LIFESPAN; MALE; OUTCOMES RESEARCH; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PROTEIN EXPRESSION; PROTEIN FAMILY; REGULATORY MECHANISM; STIMULUS;

EID: 3042582295     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. AMBDUKAR SV, DEY S, HRYCYNA CA, RAMACHANDRA M, PASTAN I, GOTTESMAN MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361-398.
2. BECK WT, GROGAN TM, WILIAM CL, CORDON-CARDO C, PARHAM DM, KUTTESH JF et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996; 56: 3100-3120.
3. BERREBI A, SHTALRID M, KLEPFISH A, BASSOUS L, KUSHNIR M, SHULMAN L et al. Verapamil inhibits B-cell proliferation and tumor necrosis factor release and induces clinical response in B-cell chronic lymphocytic leukemia. Leukemia 1994; 8: 2214-2216.
4. BOSANQUET AG, BELL PB, BURLTON AR, AMOS TA. Correlation of bcl-2 with P-glycoprotein expression in chronic lymphocytic leukemia and other haematological neoplasms but of neither marker with ex vivo chemosensitivity or patient survival. Leuk Lymphoma 1996; 24: 141-147.
5. BURGER H, NOOTER K, SONNEVELD P, VAN WINGERDEN KE, ZAMAN GJ, STOTER G. High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocytic leukaemia. Br J Haematol 1994; 88: 348-356.
6. BURGER JA, TSUKADA N, BURGER M, ZVAIFLER NJ, DELL'AQUILA M, KIPPS TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000; 96: 2655-2663.
7. CATOVSKY D, FOOKS J, RICHARDS S. Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial of MRC Working Party on Leukaemia in Adults. Br J Haematol 1989; 72: 141-149.
8. CHAOUCHI N, WALLON C, GOUJARD C, TERTIAN G, RUDENT A, CAPUT D et al. Interleukin-13 inhibits interleukin-2-induced proliferation and protects chronic lymphocytic leukemia B cells from in vitro apoptosis. Blood 1996; 1022-1029.
9. CONSOLI U, SANTONOCITO A, STAGNO F, FIUMARA P, PRIVITERA A et al. Multidrug resistance mechanisms in chronic lymphocytic leukaemia. Br J Haematol 2002; 116: 774-780.
10. DANCESCU M, RUBIO-TRUJILLO M, BIRON G, BRON D, DELESPESSE G, SARFATI M. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992; 176: 1319-1326.
11. DEL POETA G, VENDITTI A, DEL PRINCIPE MI, MAURILLO L, BUCCISANO F, TAMBURINI A et al. Amount of spontaneous apoptosis detected by bcl-2/bax ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003; 101: 2125-2131.
12. DRACH J, GSUR A, HAMILTON G, ZHAO S, ANGERLER J et al. Involvement of P-gp in the transmembrane transport of Interleukin-2, IL-4 and interferone gamma in normal human T-lymphocytes. Blood 1996; 88: 1747-1754.
13. FRIEDENBERG WR, SPENCER SK, MUSSER C, HOGAN TF, RODVOLD KA et al. Multi-drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma 1999; 34: 171-178.
14. GANESHAGURU K, WICKREMASINGHE RG, JONES DT, GORDON M, HARTSM et al. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica 2002; 87: 167-176.
15. GOLLAPUD S, GUPTA S. Anti-P-glycoprotein antibody-induced apoptosis of activated peripheral blood lymphocytes: a possible role of P-glycoprotein in lymphocyte survival. J Clin Immunol 2001; 21: 420-430.
16. HANADA M, DELIA D, AIELLO A, STADTMAUER E, REED J. bcl-2 gene hypomethylation and high-level expression in B-cell lymphocytic leukemia. Blood 1993; 82: 1820-1828.
17. HUANG RW, TSUDA H, TAKATSUKI K. Interleukin-2 prevents programmed cell death in chronic lymphocytic leukemia cells. Int J Hematol 1993; 58: 83-92.
18. JAMROZIAK K, SMOLEWSKI P, ROBEY RW, CEBULA B, BALCERCZAK E, MIROWSKI M et al. Expression of ABC family transporters: breast cancer resistance protein (ABCG2) and P-glycoprotein in Chronic Lymphocytic Leukemia (CLL). Proceedings of AACR Annual Meeting 2003: Cancer Res 2003; 44: 136.
19. JOHNSTONE RW, CRETNEY E, SMYTH MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 1999; 93: 1075-1085.
20. KITADA S, ZAPATA JM, ANDREEFF M, REED JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000; 96: 393-397.
21. KOOPMAN G, REUTELINGSPERGER CP, KUIJTEN GA, KEEHNEN RM, PALS ST, VAN OERS MH. Annexine V for flow cytometric detection of phosphatydylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415-1420.
22. LAGNEAUX L, DELFORGE A, BRON D, DE BRUYN C, STRYCKMANS P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998; 91: 2387-2396.
23. LAI GM, CHEN YN, MICKLEY LA, FOJO AT, BATES SE. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 1991; 49: 696-703.
24. LEITH CP, CHEN IM, KOPECKY KJ, APPELBAUM FR, HEAD DR et al. Correlation of multidrug resistance (MDR1) protein expression with dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR1-/efflux+ and MDR1+/efflux-cases. Blood 1995; 86: 2329-2324.
25. OLIVEIRA GB, PEREIRA FG, METZE K, LORAND-METZE. Spontaneous apoptosis in chronic lymphocytic leukemia and its relationship to clinical and cell kinetic parameters. Cytometry 2001; 46: 329-335.
26. PALLIS M, RUSSELL N. P-glycoprotein expression is associated with resistance to spontaneous in vitro apoptosis in AML. Leukemia 1999; 13: 1468-1469.
27. PALLIS M, RUSSELL N. P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood 2000; 95: 2897-2904.
28. PETTITT AR, MORAN EC, CAWLEY JC. Homotypic interactions protect chronic lymphocytic cells from spontaneous death in vitro. Leuk Res 2001; 25: 1003-1012.
29. RINGSHAUSEN I, SCHNELLER F, BOGNER C, HIPP S, DUYSTER J et al. Constitutively activated phosphophatidyylinoinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase C delta. Blood 2002; 100: 3741-3748.
30. RUEFLI AA, SMYTH MJ, JOHNSTONE RW. HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. Blood 2000; 95: 2378-2385.
31. RUEFLI AA, TAINTON KM, DARCY PK, SMYTH MJ, JOHNSTONE RW. P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ 2002; 9: 1266-1272.
32. SHUSTIK C, GROULX N, GROS P. Analysis of multidrug resistance (MDR-1) gene expression in chronic lymphocytic leukaemia (CLL). Br J Haematol 1991; 79: 50-56.
33. SMOLEWSKI P, BEDNER E, DU L, HSIEH TC, WU JM et al. Detection of caspases activation by fluorochrome-labeled inhibitors: multiparameter analysis by laser scanning cytometry. Cytometry 2001; 44: 73-82.
34. SMYTH MJ, KRASOVSKIS E, SUTTON VR, JOHNSTONE RW. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 1998; 95: 7024-7029.
35. STEINER H, POLLIACK A, KIMCHI-SARFATY C, LIBSTER D, FIBACH E, RUND D. Differences in rhodamine-123 efflux in B-type chronic lymphocytic leukemia suggest possible gender and stage variations in drug-resistance gene activity. Ann Hematol 1998; 76: 189-194.
36. SVOBODA-BEUSAN I, KUSEC R, BENDELJA K, TUDORIC-GHEMO I, JAKSIC B et al. The relevance of multidrug resistance-associated P-glycoprotein expression in the treatment response of B-cell chronic lymphocytic leukemia. Haematologica 2000; 85: 1261-1267.
37. SZMIGIELSKA-KAPLON A, SMOLEWSKI P, NAJDER M, ROBAK T. Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia. Ann Hematol 2002; 81: 508-513.
38. VILPO J, KOSKI T, VILPO L. Calcium antagonists potentiate P-glycoprotein-independent anticancer drugs in chronic lymphocytic leukemia cells in vitro. Haematologica 2000; 85: 806-813.